Artery tertiary lymphoid organs (ATLOs) are atherosclerosis-associated lymphoid aggregates with varying degrees of complexity ranging from small T/B-cell clusters to well structured lymph node-like though unencapsulated lymphoid tissues. ATLOs arise in the connective tissue that surrounds diseased arteries, i.e. the adventitia. ATLOs have been identified in aged atherosclerosis-prone hyperlipidemic apolipoprotein-deficient (ApoE-/-) mice: They are organized into distinct immune cell compartments including separate T-cell areas, activated B-cell follicles, and plasma cell (PC) niches. Analyses of ATLO immune cell subsets indicate antigen-specific T- and B-cell immune reactions within the atherosclerotic arterial wall adventitia. Moreover, ATLOs harbor innate immune cells including a large component of inflammatory macrophages, B-1 cells, and an aberrant set of antigen-presenting cells (APCs). There is marked neoangiogenesis, irregular lymphangiogenesis, neoformation of high endothelial venules (HEVs), and de novo synthesis of lymph node-like conduits. Molecular mechanisms of ATLO formation remain to be identified though media vascular smooth muscle cells (VSMCs) may adopt features of lymphoid tissue organizer- (LTo) like cells by expressing lymphorganogenic chemokines, i.e. CXCL13 and CCL21. Although these data are consistent with the view that ATLOs participate in primary T- and B-cell responses against elusive atherosclerosis-specific autoantigens, their specific protective or disease-promoting roles remain to be identified. In this review, we discuss what is currently known about ATLOs, their potential impact on atherosclerosis, and make attempts to define challenges ahead.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: